100 results
DEFA14A
MIRM
Mirum Pharmaceuticals Inc
23 Apr 24
Additional proxy soliciting materials
4:21pm
Definitive Additional Materials
Soliciting Material Pursuant to § 240.14a-12
Mirum Pharmaceuticals, Inc.
(Name of Registrant as Specified In Its Charter)
N … paid previously with preliminary materials
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
8-K
xul9a
8 Jan 24
Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates
8:30am
8-K
EX-99.2
66s7z69n1
8 Jan 24
Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates
8:30am
424B5
1qdjjtwcfy22j 8cv6s
2 Nov 23
Prospectus supplement for primary offering
4:59pm
8-K/A
EX-99.4
du93ib6 864q1i47xpwe
2 Nov 23
Financial Statements and Exhibits
4:05pm
8-K/A
EX-99.3
zk2h9l5yibs3j
2 Nov 23
Financial Statements and Exhibits
4:05pm
8-K
EX-99.1
itefq1tsrr 33nzkyd
13 Oct 23
Other Events
4:16pm
8-K
EX-10.1
bkchyq9uf
30 Aug 23
Departure of Directors or Certain Officers
4:15pm
8-K
EX-10.1
oh9u6eax
17 Jul 23
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
8:16am
8-K
EX-10.2
7irbhz bgqci
17 Jul 23
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
8:16am
8-K
EX-2.1
yac t6esjn1vvd
17 Jul 23
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
8:16am